LivaNova - Page title

Press Releases

Jul 07, 2020

LivaNova Announces Publication Detailing the Design of the RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression

LONDON --(BUSINESS WIRE)--Jul. 7, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a publication in Contemporary Clinical Trials 1 , which details the design for “A P r ospective, Multi-c e nter, Randomized C ontrolled Blinded Trial Dem...Read More
Jun 29, 2020

LivaNova to Host Conference Call for Second Quarter 2020 Results

LONDON --(BUSINESS WIRE)--Jun. 29, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second quarter 2020 results on Wednesday, July 29, 2020 at 12 p.m.   London time ( 7 a.m. Eastern Daylight Time )....Read More
Jun 12, 2020

LivaNova Announces Pricing of Private Offering of $250 Million of 3.00% Cash Exchangeable Senior Notes Due 2025

LONDON --(BUSINESS WIRE)--Jun. 12, 2020-- LivaNova PLC (NASDAQ:LIVN) (“LivaNova”) today announced the pricing of $250 million aggregate principal amount of 3.00% cash exchangeable senior notes due 2025 to be issued by its wholly owned U.S. subsidiary, LivaNova USA, Inc....Read More
Jun 11, 2020

LivaNova Announces Proposed Private Offering of $250 Million of Cash Exchangeable Senior Notes

LONDON --(BUSINESS WIRE)--Jun. 11, 2020-- LivaNova PLC (NASDAQ:LIVN) (" LivaNova ") today announced its intention to offer $250 million aggregate principal amount of cash exchangeable senior notes due 2025 through its wholly owned U.S. subsidiary, LivaNova USA, Inc....Read More
Jun 11, 2020

LivaNova Announces New Senior Secured Credit Facility

LONDON --(BUSINESS WIRE)--Jun. 11, 2020-- LivaNova PLC (NASDAQ:LIVN) (“The Company” or “LivaNova”) today announced its entry into a five-year $450 million senior secured credit facility (the “Credit Facility”) through its wholly owned U.S. subsidiary, LivaNova USA, Inc....Read More
Jun 01, 2020

LivaNova to Present at the Jefferies Virtual Healthcare Conference

LONDON --(BUSINESS WIRE)--Jun. 1, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Thad Huston , Chief Financial Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4 at 11 a.m. Eastern Time ....Read More
May 28, 2020

New Data on LivaNova Perceval Sutureless Aortic Valve Show Consistent Outcomes, Lower Procedure Times Compared to Sutured Valves

PERSIST-AVR study results presented at American Association for Thoracic Surgery Annual Meeting LONDON --(BUSINESS WIRE)--May 28, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, presented the first data from the Perceval ® Sutureless Implant Versus...Read More
May 20, 2020

New Study Shows Significant Positive Impact of Vagus Nerve Stimulation Therapy for Patients with Treatment-Resistant Bipolar Depression

LONDON --(BUSINESS WIRE)--May 20, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the publication of a new study in the International Journal of Bipolar Disorders 1 that showed adding Vagus Nerve Stimulation Therapy (VNS Therapy ® ) to...Read More
May 19, 2020

LivaNova to Present PERSIST-AVR Findings at American Association for Thoracic Surgery 100th Annual Meeting

LONDON --(BUSINESS WIRE)--May 19, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will present new findings from its Perceval ® Sutureless Implant Versus Standard-Aortic Valve Replacement (PERSIST-AVR) clinical study at the 100 th Annual Meeting of the...Read More
May 11, 2020

LivaNova to Present at the UBS Virtual Global Healthcare Conference

LONDON --(BUSINESS WIRE)--May 11, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced Damien McDonald , Chief Executive Officer, will present at the UBS Virtual Global Healthcare Conference on Wednesday, May 20 at 10:50 a.m. Eastern Time ....Read More
Apr 29, 2020

LivaNova Reports First Quarter 2020 Results

LONDON --(BUSINESS WIRE)--Apr. 29, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2020 . For the first quarter of 2020, worldwide sales from continuing operations were $242.4 million , a decrease...Read More
Apr 27, 2020

LivaNova Bi-Flow Cannula Receives CE Mark for ECMO Applications

Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days’ use LONDON --(BUSINESS WIRE)--Apr. 27, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned...Read More
Apr 22, 2020

LivaNova Permitted to Modify Cardiopulmonary Products' Indications for Use to Include ECMO Therapy Beyond Six Hours to Address COVID-19

Various products can now be used to treat patients experiencing acute respiratory or cardiopulmonary failure LONDON --(BUSINESS WIRE)--Apr. 22, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced that several of its cardiopulmonary products...Read More
Mar 30, 2020

LivaNova to Host Conference Call for First Quarter 2020 Results

LONDON --(BUSINESS WIRE)--Mar. 30, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first quarter 2020 results on Wednesday, April 29, 2020 at 1 p.m. London time ( 8 a.m. Eastern Daylight Time )....Read More
Mar 26, 2020

LivaNova Autonomic Regulation Therapy for Heart Failure Findings to be Presented at American College of Cardiology and World Congress of Cardiology Virtual Meeting

LONDON --(BUSINESS WIRE)--Mar. 26, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced two abstracts focused on implantable neuromodulation technology for patients with heart failure will be shared at this year’s American College of...Read More
Mar 09, 2020

LivaNova VNS Therapy System, Symmetry, Granted CE Mark for Difficult-to-Treat Depression

Two UK patients receive innovative VNS Therapy implantable device through new pathway LONDON --(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Vagus Nerve Stimulation Therapy ® (VNS Therapy) System, Symmetry™, earned CE...Read More
Feb 26, 2020

LivaNova Enters Research Collaboration with Verily to Gain New Insights into Vagus Nerve Stimulation Impact on Difficult-to-Treat Depression

RECOVER sub-study will leverage Verily research tools to provide quantitative assessment measures of depressive episodes LONDON --(BUSINESS WIRE)--Feb. 26, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced a research collaboration with...Read More
Feb 26, 2020

LivaNova Reports Fourth Quarter and Full-Year 2019 Results

LONDON --(BUSINESS WIRE)--Feb. 26, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2019 . For the fourth quarter of 2019, worldwide sales were $287.6 million , a decrease of 3.2...Read More
Feb 25, 2020

LivaNova Receives FDA Clearance for 3T Heater-Cooler Device Modification

LONDON --(BUSINESS WIRE)--Feb. 25, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for a device modification to its 3T Heater-Cooler ® devices....Read More
Feb 19, 2020

New International Consensus Statement Proposes “Difficult-to-treat Depression” as a More Clinically Useful Definition than “Treatment-Resistant Depression”

LONDON --(BUSINESS WIRE)--Feb. 19, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, commends the recent international consensus statement published in the Journal of Affective Disorders for recommendations to identify, assess and manage depression for...Read More
Jan 28, 2020

LivaNova to Host Conference Call for Fourth Quarter and Full-Year 2019 Results

LONDON --(BUSINESS WIRE)--Jan. 28, 2020-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth quarter and full-year 2019 results on Wednesday, Feb. 26, 2020 at 1 p.m. London time ( 8 a.m. Eastern Standard Time )....Read More